ReviewAnnals of medicine and surgery (2012)2025
The synergistic potential of camrelizumab and rivoceranib in advanced hepatocellular carcinoma: a review of current evidence.
Review in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Perioperative camrelizumab plus rivoceranib in resectable hepatocellular carcinoma: translating CARES-009 outcomes into a new therapeutic paradigm.Annals of medicine and surgery (2012) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Camrelizumab, a PD-1 inhibitor, and rivoceranib, a VEGFR tyrosine kinase inhibitor, have emerged as a promising combination therapy for advanced or unresectable hepatocellular carcinoma (HCC). This review explores the clinical efficacy and therapeutic potential of this dual treatment approach. A comprehensive literature search was conducted using PubMed/MEDLINE and Google Scholar to evaluate key clinical trials, including the pivotal CARES-310 trial. The final analysis of CARES-310 demonstrated a median overall survival (OS) of 23.8 months with camrelizumab plus rivoceranib, significantly higher than the 15.2 months observed with sorafenib (HR, 0.64; 95% CI, 0.52-0.79;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.